

Target Price: SAR53.0/share
Market price: SAR43.45/share
Upside: +22% (+Div. Yield: 4.6%)

Rating: Overweight

Alujain Corp.

NATPET deal unlocks significant value; Remain Overweight

- Alujain inked a deal to sell a 35% stake in its sole operating asset, NATPET, for SAR1.87bn (~SAR50 per share) to a chemical giant LyondellBasell Industries unit.
- The deal unlocks a significant value in Alujain, providing enough cushion to fund its PDH-PP expansion and getting LYB as a strategic partner in addition to several marketing, volume, and cost-sharing agreements.
- LYB values NATPET at SAR5.3bn, implying a significant premium over its pre-deal market cap (SAR2.9bn). We reiterate our TP of SAR53.0/sh. based on an equal blend of DCF (9.5% WACC) and EV/EBITDA valuation (10x on 2024e EBITDA).

Alujain signs an agreement to sell a 35% stake in NATPET for SAR1.87bn. Alujain has inked a deal to sell a 35% stake (representing 37.45mn shares) of its subsidiary, NATPET (98.7% stake as per the latest release) to Basell International Holdings, a unit of NY-listed LyondellBasell Industries (LYB), for ~ SAR1.87bn (US\$500mn).

- The deal: In addition to a 35% stake in NATPET, LYB will also get a 35% stake in NATPET's 600ktpa PDH-PP expansion (capex: SAR7.5bn; of which ~SAR2bn would be equity financing; 24kbpd of Propane already secured by Alujain from the MoE). Further, the deal includes the signing of multiple agreements, including i) a marketing and offtake agreement, ii) an allocation of volume agreement, iii) a project management agreement and iv) a cost-sharing and reimbursement agreement. The deal is expected to be completed once the conditions of the agreement have been fulfilled and the necessary approvals have been obtained.
- Deal size and use of proceeds: Upon completion of the deal, Alujain will receive SAR1.87bn in cash, which it plans to use to pay its current and future financial obligations. In addition, Alujain will also receive a proportion of the investment made (SAR250-300mn already spent) in the new project upon the conclusion of the comprehensive design phase in addition to a development bonus (~SAR100mn implied LYB's share + some premium) post obtaining the final approvals for investment in the new project.

Figure 1: Key financial metrics*

SARmn	2022 a	2023 e	2024 e	2025e
Revenue	1,911	1,651	1,763	1,834
Revenue growth	NM	-14%	7%	4%
Gross Profit	404	283	374	406
Gross Profit margin	21%	17%	21%	22%
EBITDA	415	321	404	430
Op. income	225	129	213	239
Net profit	120	38	155	188
Net profit margin	6%	2%	9%	10%
EPS (SAR)	1.7	0.5	2.2	2.7
P/E	25.1x	79.5x	19.4x	16.0x

Source: Company data, GIB Capital. * Before the deal

Stock data TASI ticker 2170 Mcap (SARmn) 3,007 Avg. Trd. Val (SARmn) 13.1 Free Float 87.9% QFI Holding 4.7% TASI FF weight 0.12%

Source: Bloomberg

Prices indexed to 100



Source: Bloomberg

Kunal Doshi +966-11-834 8372

Kunal.doshi@gibcapital.com



- Our take: We see this deal as a positive development, which will unlock significant value in Alujain. The agreement will complement Alujain's current growth initiatives into high-end co-polymer grades (HPGs) and high-value PP Compounds (HVPs) as well as strengthen its global competitiveness and business sustainability. This deal will also help the company in improving leverage (SAR1bn total debt as of 9M23; likely debt-free post the deal), as well as provide financial muscle to fund its expansion project (Alujain's likely total equity contribution: ~SAR1.3bn; out of this, it almost secured SAR400mn as explained above). Overall, an inflow of SAR1.87bn and bringing the global chemical giant, LYB, as a strategic partner, will ease the project financing concerns and significantly de-risk its growth plans.
- Valuation impact: Based on a back-of-the-envelope calculation, LYB values NATPET at SAR5.3bn, implying a 2.1x multiple over its current book value of SAR2.5bn (as of Nov 2023) and 1.8x of Alujain's market cap (SAR2.9bn pre-deal). We believe that this premium could be due to its expansion project in which LYB will also get a 35% stake. We note that despite announcing a big PDH-PP expansion project (600ktpa vs the existing plant capacity of 400ktpa), and strong management team track record (delivering a great turnaround from a fire incident at NATPET in 2018 to building a new plant and gaining a controlling interest in NATPET), the stock has been trading at 0.9x P/B multiple (vs. peers' average of 1.3x), which is unwarranted in our view.

Overall, we maintain our TP at SAR53/sh with an Overweight rating, given that the timing of deal completion is still uncertain, and the PDH-PP expansion is still far away (EPC contracts are expected to be awarded by June 2024; likely to begin operation in 1H26e). Any positive outcome on the deal will act as an upside risk to our valuation and may push our TP upwards by ~13% (implying a total upside of +35% from the current level).

Risks to our view:

- **Expansions:** Expansions come with its own risks. Such a huge expansion plan could dent profitability in its early years, especially when interest rates are relatively high.
- **Shutdowns:** Given that its closest competitor in terms of product mix is APPC, usually shutdowns are compared with that of APPC. Thus, there might be a valuation discount applied to Alujain if the number of shutdowns is frequent (APPC sets the benchmark with one shutdown every three years).
- Volatility in product and feedstock prices: Petrochemical prices are subject to demandsupply market dynamics. Any significant variation in these prices compared to our estimates may impact our valuation.



Disclaimer

This research report has been prepared by GIB Capital, Riyadh, Saudi Arabia. It has been prepared for the general use of GIB Capital's clients and may not be altered, redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of GIB Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by GIB Capital. The information contained was obtained from various public sources believed to be reliable, but we do not guarantee its accuracy. GIB Capital makes no representations or warranties (express or implied) regarding the data and information provided and GIB Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. GIB Capital or its officers (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. GIB Capital may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. GIB Capital and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document. Where the report contains or refers to a recommendation about a specific security or securities service, please note that it may not be suitable for all recipients. Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations. The subjectivity in future expectations is complex and may miss actual or reported numbers.

This research document and any recommendations contained are subject to change without prior notice. GIB Capital assumes no responsibility to update the information in this research document. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law, or which would subject GIB Capital to any registration or licensing requirement within such jurisdiction

The principal activities of GIB Capital are Dealing, Custody, Managing, Arranging and Advising pursuant to the Capital Market Authority ("CMA") License No. 07078-37.

We use a rating system based on potential upside, 1 year from today, based on our valuation models. For "Overweight" ratings, the estimated upside is >10%, for "Underweight", the estimated downside is <10%. For returns in between +/-10%. we have a Neutral rating.

Contact us for queries:

Sell Side Research Department, GIB Capital, B1, Granada Business & Residential Park, Eastern Ring Road, PO Box 89589, Riyadh 11692 www.gibcapital.com